Get the Stockscreener App
2.02
0.25%
-0.005
After Hours:
2.02
Xortx Therapeutics Inc stock is traded at $2.02, with a volume of 18,137.
It is down -0.25% in the last 24 hours and down -7.76% over the past month.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
See More
Previous Close:
$2.025
Open:
$2.01
24h Volume:
18,137
Relative Volume:
0.42
Market Cap:
$3.50M
Revenue:
-
Net Income/Loss:
$-2.77M
P/E Ratio:
-0.7633
EPS:
-2.6464
Net Cash Flow:
$-2.69M
1W Performance:
+0.50%
1M Performance:
-7.76%
6M Performance:
-24.58%
1Y Performance:
-51.62%
1-Day Range:
$1.95
$2.14
1-Week Range:
$1.95
$2.17
52-Week Range:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.02 | 3.50M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
Why XORTX Therapeutics Inc stock is sliding today - Wealth Awesome
XORTX Therapeutics Inc (XRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XORTX Therapeutics Inc (XRTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XRTX|XORTX Therapeutics Inc|Price:2.025|Chg%:-0.090 - TradingKey
XORTX Therapeutics Inc (XRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
XORTX Therapeutics Inc (XRTX) Institutional Confidence - TradingKey
XORTX Therapeutics Inc (XRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XORTX Therapeutics Inc (XRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XORTX Therapeutics Inc. Revenue Breakdown – NASDAQ:XRTX - TradingView
XORTX Therapeutics Inc (XRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XORTX Therapeutics, Inc. Revenue Breakdown – NEO:XRTX - TradingView
XORTX Therapeutics(XRTX) Stock Options Chain | Quotes & News - Moomoo
XORTX Therapeutics (XRTX) Investor presentation Summary - Quartr
XORTX Therapeutics (XRTX) Q4 2024 earnings summary - Quartr
Price to earnings forward of XORTX Therapeutics, Inc. – LSX:A427MJ - TradingView
XORTX Therapeutics (XRTX) Rallies 3.3% as Biotech Sector Gains MomentumMoney Flow - dars.gov.et
XORTX Therapeutics (XRTX) Gains 3.33% as Biotech Momentum BuildsDescending Triangle - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Xortx Therapeutics updates investors on kidney disease focus - ad-hoc-news.de
XORTX Therapeutics Company Profile & Introduction - Moomoo
XRTX Q1 2024 Earnings: Significant EPS Miss Reflects Preclinical Stage ChallengesQuarterly Earnings - dars.gov.et
Enterprise value to EBIT forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Price to sales forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Enterprise value to revenue forward of XORTX Therapeutics, Inc. – TSXV:XRTX - TradingView
Why XORTX Therapeutics Inc stock is skyrocketing today - Wealth Awesome
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
XRTX Q1 2024 Earnings: Significant EPS Miss Highlights Challenges in Clinical-Stage BiotechEarnings Growth Analysis - dars.gov.et
XRTX Q1 2024 Earnings: Significant EPS Miss Amid Operational DevelopmentsEarnings Surprise Stocks - DonanımHaber
XORTX Therapeutics (XRTX) Edges Higher as Stock Remains Within Defined RangeLong Short Pair - DonanımHaber
XORTX Therapeutics Inc. (XRTX) Slides 2.79% as Shares Test Key Support Near $2.00IV Percentile - dars.gov.et
XORTX Therapeutics Inc (XRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XORTX Therapeutics Inc (XRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
XORTX Therapeutics Q1 2024 Earnings: Significant EPS Miss Reflects R&D Investment, Stock Gains Despite Loss - newsline.com
XORTX Therapeutics (XRTX) Slips 0.68% as Traders Eye Key Support at $2.06Covered Call ETF - newsline.com
XORTX Therapeutics appoints Mika Grasso as co‑CEO - MSN
XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange - marketscreener.com
XORTX Therapeutics Inc. Announces Appointment of Mika Grasso to Co-CEO - marketscreener.com
XORTX Therapeutics Providing Corporate Update and Appoints Mika Grasso as Co-CEO - marketscreener.com
XORTX Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
XORTX Therapeutics (NASDAQ: XRTX) refocuses on gout program and appoints co-CEO - Stock Titan
A 28-year-old co-CEO and XORTX's $700M gout push in the US - Stock Titan
XORTX appoints Mika Grasso as Co-CEO and advances gout drug XRx-026 towards FDA approval. - Pluang
XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing - The Globe and Mail
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange - The Manila Times
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | Associated Press | syndication news - Enidnews.com
XORTX Therapeutics (NASDAQ: XRTX) to voluntarily delist from TSX Venture - Stock Titan
XORTX Therapeutics to voluntarily delist from T... - Pluang
XRTX Stock Chart | XORTX THERAPEUTICS INC (NASDAQ:XRTX) - ChartMill
XORTX Therapeutics (XRTX) Slides Over 3% as Biotech Stock Tests Key Support LevelsTrend Reversal Picks - newsline.com
XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading SessionSkew Index - thelegaladvocate.com
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):